Janet Roberts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Janet Roberts has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Carrie Ye
McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary , Calgary AB
6 shared publications - Aurore Fifi-Mah
A.V. Fifi-Mah, MD, Department of Medicine, University of Calgary, Calgary, Alberta
4 shared publications - Claire E. H. Barber
Department of Community Health Sciences Cumming School of Medicine, University of Calgary Calgary Alberta Canada
4 shared publications - Janet Elizabeth Pope
University of Western Ontario, London, Ontario, Canada
4 shared publications - Shahin Jamal
University of British Columbia Vancouver British Columbia Canada
4 shared publications - Lourdes Gonzalez Arreola
L.G. Arreola, MSc, Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada, Vancouver, British Columbia
3 shared publications
Latest Publications
- Open Access
- 20 April 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (10) , 2160-2170
Validation of International Classification of Diseases Code–Based Case Definitions of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis From Administrative Health Data
Objective: Immune checkpoint inhibitors (ICIs) for cancer can lead to immune‐related adverse events, including ICI‐associated inflammatory arthritis (ICI‐IA). There are no validated International Classification of Diseases (ICD) code–based case definitions for ICI‐IA. Methods: We conducted a validation study using the Canadian Research Group of Rheumatology in Immuno‐Oncology (CanRIO) database. Rheumatologist‐confirmed ICI‐IA was the reference standard, defined as new onset of at least one swollen joint on examination or synovitis on imaging following ICI exposure, without another cause or pre‐existing IA. We compared ICD‐9 (714.x and 696.0) and ICD‐10 (M05.x, M06.x, and M07.x) IA diagnostic codes against the reference standard. Seven core case definitions of different combinations of ICD codes from the Physician Claims Database (PCD) and the Discharge Abstract Database were tested. Results were stratified by sex. Sensitivity testing with additional criteria was also evaluated. Results: We included 228 patients in the final analysis: 100 with ICI‐IA and 128 without ICI‐IA. Sensitivity of the tested case definitions ranged from 1.0% to 88.0%, whereas specificity ranged from 86.7% to 100.0%. The case definition with at least one PCD IA code achieved the best balance of sensitivity (88.0%, 95% confidence interval [CI] 81.6%–94.4%) and specificity (86.7%, 95% CI 80.8%–92.6%). Case definition performances were similar between sexes. Additional criteria minimally improved specificity but sacrificed sensitivity. Conclusion: ICD code–based case definitions of ICI‐IA can accurately detect ICI‐IA and can be used to support ICI‐IA surveillance and research with administrative health data.
- 20 April 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (10) , 2160-2170
Open AccessValidation of International Classification of Diseases Code–Based Case Definitions of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis From Administrative Health Data
Objective: Immune checkpoint inhibitors (ICIs) for cancer can lead to immune‐related adverse events, including ICI‐associated inflammatory arthritis (ICI‐IA). There are no validated International Classification of Diseases (ICD) code–based case definitions for ICI‐IA. Methods: We conducted a validation study using the Canadian Research Group of Rheumatology in Immuno‐Oncology (CanRIO) database. Rheumatologist‐confirmed ICI‐IA was the reference standard, defined as new onset of at least one swollen joint on examination or synovitis on imaging following ICI exposure, without another cause or pre‐existing IA. We compared ICD‐9 (714.x and 696.0) and ICD‐10 (M05.x, M06.x, and M07.x) IA diagnostic codes against the reference standard. Seven core case definitions of different combinations of ICD codes from the Physician Claims Database (PCD) and the Discharge Abstract Database were tested. Results were stratified by sex. Sensitivity testing with additional criteria was also evaluated. Results: We included 228 patients in the final analysis: 100 with ICI‐IA and 128 without ICI‐IA. Sensitivity of the tested case definitions ranged from 1.0% to 88.0%, whereas specificity ranged from 86.7% to 100.0%. The case definition with at least one PCD IA code achieved the best balance of sensitivity (88.0%, 95% confidence interval [CI] 81.6%–94.4%) and specificity (86.7%, 95% CI 80.8%–92.6%). Case definition performances were similar between sexes. Additional criteria minimally improved specificity but sacrificed sensitivity. Conclusion: ICD code–based case definitions of ICI‐IA can accurately detect ICI‐IA and can be used to support ICI‐IA surveillance and research with administrative health data.
- Open Access
- 2 January 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (1)
Development and validation of a clinical risk prediction rule to identify inflammatory arthritis at the point of rheumatology triage
Objectives: To develop and validate a clinical prediction rule to identify inflammatory arthritis (IA) using routinely collected triage data, without ACPA. Methods: Prospective observational data from 184 patients referred to a tertiary care rheumatology clinic for joint pain over a 9-month period and meeting inclusion criteria were used to derive a clinical risk prediction rule for the diagnosis of IA versus non-IA, utilizing penalized and stepwise logistic regression modelling, including age, sex, CRP and RF. Internal validation was performed using 5-fold cross-validation. A population within the UK Biobank with a diagnosis of incident IA or non-IA, within 180 days of baseline assessment (N = 2828), was used for broad external domain validation. Model performance was assessed by the c-statistic (cvAUC) and the Hosmer–Lemeshow test. Results: In the derivation cohort, CRP had the strongest association with diagnosis of IA in both models, other important predictors being sex and CRP twice the upper limit of normal in the stepwise model (cvAUC = 0.72, 95% CI 0.58, 0.85) and additionally RF and age in the penalized regression model (cvAUC = 0.77, 95% CI 0.59, 0.95). When applied in the UK Biobank, AUC values decreased (0.54–0.55); however, limitations in accurately defining the timing of incident arthritis indicate the need for geographical validation in a cohort that better fits the target population and setting. Conclusions: This simple prediction rule, utilizing demographic and laboratory data, performed well in discriminating IA from non-IA in the derivation population. Additional validation studies in similar clinical settings are required to further refine the model and determine generalizability.
- 2 January 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (1)
Open AccessDevelopment and validation of a clinical risk prediction rule to identify inflammatory arthritis at the point of rheumatology triage
Objectives: To develop and validate a clinical prediction rule to identify inflammatory arthritis (IA) using routinely collected triage data, without ACPA. Methods: Prospective observational data from 184 patients referred to a tertiary care rheumatology clinic for joint pain over a 9-month period and meeting inclusion criteria were used to derive a clinical risk prediction rule for the diagnosis of IA versus non-IA, utilizing penalized and stepwise logistic regression modelling, including age, sex, CRP and RF. Internal validation was performed using 5-fold cross-validation. A population within the UK Biobank with a diagnosis of incident IA or non-IA, within 180 days of baseline assessment (N = 2828), was used for broad external domain validation. Model performance was assessed by the c-statistic (cvAUC) and the Hosmer–Lemeshow test. Results: In the derivation cohort, CRP had the strongest association with diagnosis of IA in both models, other important predictors being sex and CRP twice the upper limit of normal in the stepwise model (cvAUC = 0.72, 95% CI 0.58, 0.85) and additionally RF and age in the penalized regression model (cvAUC = 0.77, 95% CI 0.59, 0.95). When applied in the UK Biobank, AUC values decreased (0.54–0.55); however, limitations in accurately defining the timing of incident arthritis indicate the need for geographical validation in a cohort that better fits the target population and setting. Conclusions: This simple prediction rule, utilizing demographic and laboratory data, performed well in discriminating IA from non-IA in the derivation population. Additional validation studies in similar clinical settings are required to further refine the model and determine generalizability.
- Open Access
- 15 September 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (12) , 1207-1217
Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 1: Preexisting Inflammatory Arthritides
Objective: Immune checkpoint inhibitors (ICIs) are being increasingly used in patients with preexisting inflammatory arthritides (IAs). However, there are concerns that concomitant baseline immunosuppression at the time of ICI initiation may worsen cancer outcomes, a risk that needs to be balanced with the risk of IA flare. The objective of this study was to develop a living guideline that will offer up-to-date guidance on the management of baseline immunosuppression for preexisting IAs when initiating cancer immunotherapy with ICIs. Methods: The Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) formed a multidisciplinary panel composed of rheumatologists, oncologists, researchers, and a patient representative, with methodological support from the Canadian Rheumatology Association (CRA). We completed a systematic literature review to inform this first installment of our living guideline. Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, the panel developed recommendations for the management of baseline immunosuppression in individuals with preexisting IAs. Results: We identified 67 relevant publications that reported on immunosuppression and cancer outcomes by specific preexisting rheumatic diseases, including 44 on preexisting IA. Eight best practice statements were developed, highlighting the importance of shared decision making between patients and their care team and careful consideration of risk of IA flare, risk of organ- or life-threatening manifestations, and the potential effect of immunosuppression on cancer outcomes. Four specific recommendations were made, one each for preexisting rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, and spondyloarthritis, considering both the available evidence and expert consensus. The general recommendation for preexisting IAs was to reduce or stop baseline immunosuppression, unless there are extraarticular organ- or life-threatening manifestations. Conclusion: This living guideline will provide contemporary baseline immunosuppression recommendations for individuals with cancer and preexisting IA when initiating ICI therapy. New recommendations will be added over time and updated, with the latest recommendations, evidence summaries, and Evidence to Decision summaries available through the CRA and CanRIO websites ( www.rheum.ca , www.canrio.ca ). (PROSPERO registration: CRD42023461024)
- 15 September 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (12) , 1207-1217
Open AccessCanadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 1: Preexisting Inflammatory Arthritides
Objective: Immune checkpoint inhibitors (ICIs) are being increasingly used in patients with preexisting inflammatory arthritides (IAs). However, there are concerns that concomitant baseline immunosuppression at the time of ICI initiation may worsen cancer outcomes, a risk that needs to be balanced with the risk of IA flare. The objective of this study was to develop a living guideline that will offer up-to-date guidance on the management of baseline immunosuppression for preexisting IAs when initiating cancer immunotherapy with ICIs. Methods: The Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) formed a multidisciplinary panel composed of rheumatologists, oncologists, researchers, and a patient representative, with methodological support from the Canadian Rheumatology Association (CRA). We completed a systematic literature review to inform this first installment of our living guideline. Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, the panel developed recommendations for the management of baseline immunosuppression in individuals with preexisting IAs. Results: We identified 67 relevant publications that reported on immunosuppression and cancer outcomes by specific preexisting rheumatic diseases, including 44 on preexisting IA. Eight best practice statements were developed, highlighting the importance of shared decision making between patients and their care team and careful consideration of risk of IA flare, risk of organ- or life-threatening manifestations, and the potential effect of immunosuppression on cancer outcomes. Four specific recommendations were made, one each for preexisting rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, and spondyloarthritis, considering both the available evidence and expert consensus. The general recommendation for preexisting IAs was to reduce or stop baseline immunosuppression, unless there are extraarticular organ- or life-threatening manifestations. Conclusion: This living guideline will provide contemporary baseline immunosuppression recommendations for individuals with cancer and preexisting IA when initiating ICI therapy. New recommendations will be added over time and updated, with the latest recommendations, evidence summaries, and Evidence to Decision summaries available through the CRA and CanRIO websites ( www.rheum.ca , www.canrio.ca ). (PROSPERO registration: CRD42023461024)
- Open Access
- 15 September 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (12) , 1218-1230
Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisting Systemic Autoimmune Rheumatic Diseases
Objective: Although immune checkpoint inhibitors (ICIs) are increasingly used in patients with preexisting systemic autoimmune rheumatic diseases (SARDs), a key concern is whether baseline immunosuppression at the start of ICI treatment might negatively affect cancer outcomes. This risk must be carefully weighed against the potential for a SARD flare. The objective of this study was to develop a living guideline that will provide up-to-date guidance on the management of baseline immunosuppression for preexisting SARDs when initiating cancer immunotherapy with ICIs. Methods: The Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) formed a multidisciplinary panel composed of rheumatologists, oncologists, researchers, and a patient representative, with methodological support from the Canadian Rheumatology Association (CRA). We completed a systematic literature review to inform this first installment of our living guideline. Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, the panel developed recommendations for the management of baseline immunosuppression in individuals with preexisting SARDs. Results: We identified 67 publications that reported on immunosuppression and cancer outcomes by specific preexisting rheumatic diseases, including 36 on preexisting SARD. Eight best practice statements were developed, highlighting the importance of shared decision making between patients and their care team and careful consideration of risk of SARD flare, risk of organ- or life-threatening manifestations, and potential effect of immunosuppression on cancer outcomes. Seven specific recommendations were made, 1 each for preexisting systemic lupus erythematosus, systemic sclerosis, Sjögren disease, myositis, sarcoidosis, vasculitis, and Behçet disease, considering both the available evidence and expert consensus. The general recommendation for preexisting SARDs was to continue baseline immunosuppression, particularly if there are organ- or life-threatening manifestations. Conclusion: This living guideline will provide contemporary baseline immunosuppression recommendations for individuals with cancer and preexisting SARDs when initiating ICI therapy. New recommendations will be added over time and updated, with the latest recommendations, evidence summaries, and Evidence to Decision summaries available through the CRA and CanRIO websites ( www.rheum.ca , www.canrio.ca ). (PROSPERO registration: CRD42023461024)
- 15 September 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (12) , 1218-1230
Open AccessCanadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisting Systemic Autoimmune Rheumatic Diseases
Objective: Although immune checkpoint inhibitors (ICIs) are increasingly used in patients with preexisting systemic autoimmune rheumatic diseases (SARDs), a key concern is whether baseline immunosuppression at the start of ICI treatment might negatively affect cancer outcomes. This risk must be carefully weighed against the potential for a SARD flare. The objective of this study was to develop a living guideline that will provide up-to-date guidance on the management of baseline immunosuppression for preexisting SARDs when initiating cancer immunotherapy with ICIs. Methods: The Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) formed a multidisciplinary panel composed of rheumatologists, oncologists, researchers, and a patient representative, with methodological support from the Canadian Rheumatology Association (CRA). We completed a systematic literature review to inform this first installment of our living guideline. Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, the panel developed recommendations for the management of baseline immunosuppression in individuals with preexisting SARDs. Results: We identified 67 publications that reported on immunosuppression and cancer outcomes by specific preexisting rheumatic diseases, including 36 on preexisting SARD. Eight best practice statements were developed, highlighting the importance of shared decision making between patients and their care team and careful consideration of risk of SARD flare, risk of organ- or life-threatening manifestations, and potential effect of immunosuppression on cancer outcomes. Seven specific recommendations were made, 1 each for preexisting systemic lupus erythematosus, systemic sclerosis, Sjögren disease, myositis, sarcoidosis, vasculitis, and Behçet disease, considering both the available evidence and expert consensus. The general recommendation for preexisting SARDs was to continue baseline immunosuppression, particularly if there are organ- or life-threatening manifestations. Conclusion: This living guideline will provide contemporary baseline immunosuppression recommendations for individuals with cancer and preexisting SARDs when initiating ICI therapy. New recommendations will be added over time and updated, with the latest recommendations, evidence summaries, and Evidence to Decision summaries available through the CRA and CanRIO websites ( www.rheum.ca , www.canrio.ca ). (PROSPERO registration: CRD42023461024)
- Open Access
- 8 September 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (4)
Treatment of severe refractory immune neutropenia with ruxolitinib: Two cases
Two adult patients with severe immune neutropenia refractory to standard therapies achieved durable remission following treatment with the JAK inhibitor ruxolitinib. This report highlights the potential of JAK–STAT pathway inhibition for managing G-CSF and steroid-refractory immune-mediated neutropenia.
- 8 September 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (4)
Open AccessTreatment of severe refractory immune neutropenia with ruxolitinib: Two cases
Two adult patients with severe immune neutropenia refractory to standard therapies achieved durable remission following treatment with the JAK inhibitor ruxolitinib. This report highlights the potential of JAK–STAT pathway inhibition for managing G-CSF and steroid-refractory immune-mediated neutropenia.
- Open Access
- 13 February 2025
- Published by Wiley in Musculoskeletal Care
- Vol. 23 (1) , e70065
Improving Knowledge Dissemination of Rheumatic Toxicities of Cancer Immunotherapy: A Web‐Based Educational Initiative
- 13 February 2025
- Published by Wiley in Musculoskeletal Care
- Vol. 23 (1) , e70065
Open AccessImproving Knowledge Dissemination of Rheumatic Toxicities of Cancer Immunotherapy: A Web‐Based Educational Initiative
- Open Access
- 15 December 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Dr. Roberts et al reply
We thank Dr. Steiman and colleagues1 for their interest and correspondence regarding our recent publication exploring the feasibility of physiotherapy-led rheumatology triage using a standardized triage algorithm.2 The algorithm used in this study relied on the referring providers9 physical examination, laboratory results, and radiographic results, as well as patient-reported questionnaire scores.
- 15 December 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Open AccessDr. Roberts et al reply
We thank Dr. Steiman and colleagues1 for their interest and correspondence regarding our recent publication exploring the feasibility of physiotherapy-led rheumatology triage using a standardized triage algorithm.2 The algorithm used in this study relied on the referring providers9 physical examination, laboratory results, and radiographic results, as well as patient-reported questionnaire scores.
- 15 December 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Objective: Immune checkpoint inhibitors (ICIs) have revolutionized cancer outcomes but are limited by immune-related adverse events (irAEs), including rheumatic irAEs (Rh-irAEs). Aging is associated with increased inflammation, referred to as "inflammaging." In this study, we explore the effect of age on severity, frequency, and treatment of Rh-irAEs.Methods: Adults with new Rh-irAEs after ICI exposure are followed prospectively across 10 Canadian sites as part of the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) prospective cohort. In this study of patients seen between January 2020 and March 2023, we compare the severity of Rh-irAEs and number of irAEs between patients aged ≥ 65 years and < 65 years and explore potential epidemiologic, treatment-related, and phenotypic differences between the older and younger patients.Results: A total of 139 patients with de novo Rh-irAEs were included, 58 in the younger (aged < 65 yrs) and 81 in the older (aged ≥ 65 yrs) group. There were no significant differences in severity of Rh-irAEs (P= 0.84) or number of irAEs (P= 0.21), although there was a nonsignificant trend toward more younger patients than older patients with ≥ 3 irAEs (24% vs 14%). Types of treatment for Rh-irAEs were similar between the groups. ICI continuation did not differ. Within the ICI-related inflammatory arthritis subgroup, there was also no significant difference in the incidence of severe Rh-irAEs (P= 0.51).Conclusion: Similar numbers of overall irAEs and severity of Rh-irAEs were observed between older vs younger patients who developed Rh-irAEs after treatment with ICI therapy, suggesting that inflammaging does not play a significant role in Rh-irAEs. Larger studies are needed to explore potential differences in patient phenotypes.
- 15 December 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Objective: Immune checkpoint inhibitors (ICIs) have revolutionized cancer outcomes but are limited by immune-related adverse events (irAEs), including rheumatic irAEs (Rh-irAEs). Aging is associated with increased inflammation, referred to as "inflammaging." In this study, we explore the effect of age on severity, frequency, and treatment of Rh-irAEs.Methods: Adults with new Rh-irAEs after ICI exposure are followed prospectively across 10 Canadian sites as part of the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) prospective cohort. In this study of patients seen between January 2020 and March 2023, we compare the severity of Rh-irAEs and number of irAEs between patients aged ≥ 65 years and < 65 years and explore potential epidemiologic, treatment-related, and phenotypic differences between the older and younger patients.Results: A total of 139 patients with de novo Rh-irAEs were included, 58 in the younger (aged < 65 yrs) and 81 in the older (aged ≥ 65 yrs) group. There were no significant differences in severity of Rh-irAEs (P= 0.84) or number of irAEs (P= 0.21), although there was a nonsignificant trend toward more younger patients than older patients with ≥ 3 irAEs (24% vs 14%). Types of treatment for Rh-irAEs were similar between the groups. ICI continuation did not differ. Within the ICI-related inflammatory arthritis subgroup, there was also no significant difference in the incidence of severe Rh-irAEs (P= 0.51).Conclusion: Similar numbers of overall irAEs and severity of Rh-irAEs were observed between older vs younger patients who developed Rh-irAEs after treatment with ICI therapy, suggesting that inflammaging does not play a significant role in Rh-irAEs. Larger studies are needed to explore potential differences in patient phenotypes.
- 8 December 2024
- Published by Taylor & Francis in Immunotherapy
- Vol. 16 (20-22) , 1247-1254
Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis
Immune checkpoint inhibitors (ICIs) are first-line treatment for melanoma. The incidence of musculoskeletal immune-related adverse events (MSK irAEs) remains unclear. To estimate the relative risk of MSK irAEs in melanoma patients treated with ICIs targeting programmed cell death-1 or its ligand PD-(L)1 as compared to placebo. We performed a systematic literature review including phase III randomized controlled trials of adult melanoma patients comparing a PD-(L)1 inhibitor to a placebo arm. Outcomes of interest included arthralgias, arthritis, back pain and myalgias. Meta-analysis was performed to estimate the pooled relative risk of MSK irAEs over the treatment course. Four RCTs met the inclusion criteria (n = 3,041 subjects). Use of PD-(L)1 inhibitors was associated with an increased risk of developing arthralgias (RR 1.30 [95% CI: 1.13-1.49]) and myalgias (RR 1.48 [95% CI: 1.17-1.87]) as compared to placebo. Back pain and arthritis were not reported. Use of PD-(L)1 inhibitors is associated with a significantly increased risk of arthralgias and myalgias in melanoma patients. The risk of back pain and arthritis is unknown. MSK irAEs can impact quality of life and should be considered, particularly in the adjuvant setting when risks and benefits are carefully weighed.
- 8 December 2024
- Published by Taylor & Francis in Immunotherapy
- Vol. 16 (20-22) , 1247-1254
Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis
Immune checkpoint inhibitors (ICIs) are first-line treatment for melanoma. The incidence of musculoskeletal immune-related adverse events (MSK irAEs) remains unclear. To estimate the relative risk of MSK irAEs in melanoma patients treated with ICIs targeting programmed cell death-1 or its ligand PD-(L)1 as compared to placebo. We performed a systematic literature review including phase III randomized controlled trials of adult melanoma patients comparing a PD-(L)1 inhibitor to a placebo arm. Outcomes of interest included arthralgias, arthritis, back pain and myalgias. Meta-analysis was performed to estimate the pooled relative risk of MSK irAEs over the treatment course. Four RCTs met the inclusion criteria (n = 3,041 subjects). Use of PD-(L)1 inhibitors was associated with an increased risk of developing arthralgias (RR 1.30 [95% CI: 1.13-1.49]) and myalgias (RR 1.48 [95% CI: 1.17-1.87]) as compared to placebo. Back pain and arthritis were not reported. Use of PD-(L)1 inhibitors is associated with a significantly increased risk of arthralgias and myalgias in melanoma patients. The risk of back pain and arthritis is unknown. MSK irAEs can impact quality of life and should be considered, particularly in the adjuvant setting when risks and benefits are carefully weighed.
- Open Access
- 22 August 2024
- Published by BMJ in BMJ Oncology
- Vol. 3 (1) , e000559
Determining fracture risk in patients exposed to immune checkpoint inhibitors: the time is now
Immune checkpoint inhibitors (ICIs) are first-line treatments for melanoma in both the metastatic and adjuvant settings.1 The success of ICIs in the treatment of melanoma is unparallelled yet tempered by the potential development of off-target effects, termed immune-related adverse events (irAEs).2 IrAEs affecting bone and its metabolism, including osteoporosis and fracture, remain infrequently described and poorly understood. Cancer treatment-induced bone loss due to androgen deprivation therapy, aromatase inhibitors and ovarian suppression therapy is well recognised, with established guidelines to assist clinicians in making informed decisions regarding prevention, monitoring and treatment.3 Given the increasing survival associated with ICIs and the potential morbidity and mortality associated with major osteoporotic fractures (MOFs), there is a growing urgency to quantify the potential risk ICIs may pose to bone health and mitigate it if possible.
- 22 August 2024
- Published by BMJ in BMJ Oncology
- Vol. 3 (1) , e000559
Open AccessDetermining fracture risk in patients exposed to immune checkpoint inhibitors: the time is now
Immune checkpoint inhibitors (ICIs) are first-line treatments for melanoma in both the metastatic and adjuvant settings.1 The success of ICIs in the treatment of melanoma is unparallelled yet tempered by the potential development of off-target effects, termed immune-related adverse events (irAEs).2 IrAEs affecting bone and its metabolism, including osteoporosis and fracture, remain infrequently described and poorly understood. Cancer treatment-induced bone loss due to androgen deprivation therapy, aromatase inhibitors and ovarian suppression therapy is well recognised, with established guidelines to assist clinicians in making informed decisions regarding prevention, monitoring and treatment.3 Given the increasing survival associated with ICIs and the potential morbidity and mortality associated with major osteoporotic fractures (MOFs), there is a growing urgency to quantify the potential risk ICIs may pose to bone health and mitigate it if possible.